Since the P2Y2 receptor and the KCa3.1 channel are co-expressed in neoplastic cells from human ovary, we propose that they may be useful tumor markers as well as targets for therapy to halt ovarian cancer progression. This evidence concerns the gene KCNN4 and ovarian carcinoma.